By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Acceleron Pharma 

128 Sidney Street

Cambridge  Massachusetts    U.S.A.
Phone: 617-649-9200 Fax: 617-649-9988


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

Alkermes 





Company News
Acceleron Pharma Provides Updated Results From Ongoing Phase II Study Of Luspatercept In Myelodysplastic Syndromes At The 22nd Congress Of The European Hematology Association 6/23/2017 6:58:19 AM
Acceleron Pharma Provides Updated Results From Phase II Studies Of Luspatercept In Beta-Thalassemia At The 22nd Congress Of The European Hematology Association 6/23/2017 6:56:37 AM
How A Celgene (CELG)-Partnered Drug Trial Could Save Struggling Acceleron Pharma 6/14/2017 5:56:58 AM
Acceleron Pharma Ditches Dalantercept After Failure Of Phase II Kidney Cancer Study 6/13/2017 5:51:38 AM
Celgene (CELG) And Acceleron Pharma Complete Target Enrollment In The MEDALIST And BELIEVE Phase III Studies Of Luspatercept In Myelodysplastic Syndromes And Beta-Thalassemia 6/1/2017 7:00:52 AM
Acceleron Pharma Announces Clinical Presentations On Luspatercept At The 22nd Congress Of European Hematology Association 5/18/2017 8:04:29 AM
Acceleron Pharma Release: Luspatercept Phase II Data Presented At The 14th International Symposium On Myelodysplastic Syndromes 5/8/2017 6:52:26 AM
Acceleron Pharma Reports First Quarter 2017 Operational And Financial Results 5/8/2017 6:17:59 AM
Acceleron Pharma Announces Management Change 5/3/2017 5:39:11 AM
Acceleron Pharma Provides Clinical Development Updates On Luspatercept Program 4/27/2017 8:36:13 AM
12345678910...
//-->